MJN up +0.76% percent right now. $MJN High is at 99.34 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
MJN up +0.76% percent right now. $MJN High is at 99.34 and the Low 98.37 with current volume of 431,817.

Recent News posted below.

MJN Mead Johnson Nutrition Company Recent Headline News

Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Mead Johnson Nutrition Is Down 2.3% (MJN)
Comtex SmarTrend(R) - Mon Nov 10, 9:35AM CST
Two weeks ago on October 23rd, 2014 Mead Johnson Nutrition (NYSE:MJN) reported earnings and analysts, on average, expected earnings of $0.90 on sales of $1.1 billion. Mead Johnson Nutrition actually reported earnings of $0.93 per share on sales of $1.1 billion, beating EPS estimates by $0.03 and beating revenue estimates by $10.7 million. Shares of Mead Johnson Nutrition have slipped from $100.66 to $98.39, representing a loss of 2.3%, since the company reported earnings 18 days ago.
MJN: 99.23 (+0.84)

My Challenges As A Dividend Growth Investor
Integrator - at Seeking Alpha - Fri Nov 07, 4:34PM CST

KO: 42.37 (+0.05), NKE: 94.99 (+1.21), HSY: 96.45 (+0.02), DIS: 89.68 (-0.32), QSII: 14.57 (+0.01), PEP: 96.87 (+0.07), SBUX: 77.78 (-0.01), JNJ: 108.84 (+0.64), V: 249.97 (-2.46), MJN: 99.23 (+0.84), MCD: 95.25 (+0.15), BP: 41.91 (-0.15), PG: 89.40 (+0.27), MELI: 136.22 (+1.47), FHCO: 4.45 (-0.04), CSCO: 25.17 (-0.16), MA: 85.01 (+0.21), CL: 68.45 (+0.40)

Insider Trading Alert - CERN, MJN And AL Traded By Insiders
at The Street - Wed Nov 05, 11:25AM CST
Stocks with insider trader activity include CERN, MJN and AL
MJN: 99.23 (+0.84), AL: 37.71 (+0.11), CERN: 63.33 (+0.32)

Quarterly Earnings, New Product, and Expansion - Research Reports on Tempur Sealy, Mead Johnson, Keurig, Mattel and Colgate
PR Newswire - Wed Nov 05, 8:05AM CST
Today, Analysts Review released its research reports regarding Tempur Sealy International Inc. (NYSE: TPX), Mead Johnson Nutrition Company (NYSE: MJN), Keurig Green Mountain, Inc. (NASDAQ: GMCR), Mattel, Inc. (NASDAQ: MAT) and Colgate-Palmolive Co. (NYSE: CL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7707-100free.
MJN: 99.23 (+0.84), MAT: 31.50 (-0.17), GMCR: 155.20 (+2.30), TPX: 54.97 (+0.42), CL: 68.45 (+0.40)

Mead Johnson Tumbles as Danone Goes for Yashili in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:20AM CST
Pediatric nutrition products provider Mead Johnson Nutrition Company's (MJN) shares dropped 4.1% to close at $99.31 on Friday.
BSX: 13.44 (+0.20), MJN: 99.23 (+0.84), GWPH: 73.89 (-0.08), ABAX: 52.72 (+1.09)

Mead Johnson Nutrition Company: Analysis Of Earnings Beat
CapitalCube - Seeking Alpha - Sun Nov 02, 8:21AM CST
The table below shows the preliminary results and recent trends for key metrics such as revenues and net income (See complete table at the end of this report): 2013-09-30 2013-12-31 2014-03-31 2014-06-30 2014-09-30 Revenues ...
MJN: 99.23 (+0.84)

Mead Johnson Nutrition Falls 4.11% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Oct 31, 4:17PM CDT
Mead Johnson Nutrition (NYSE:MJN) traded in a range yesterday that spanned from a low of $96.72 to a high of $101.26. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $101.02 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MJN: 99.23 (+0.84)

Mead Johnson Nutrition (MJN): Today's Weak On High Volume Stock
at The Street - Fri Oct 31, 9:04AM CDT
Trade-Ideas LLC identified Mead Johnson Nutrition (MJN) as a weak on high relative volume candidate
MJN: 99.23 (+0.84)

Look for Shares of Mead Johnson Nutrition to Potentially Pullback after Yesterday's 2.71% Rise
Comtex SmarTrend(R) - Fri Oct 24, 5:04PM CDT
Mead Johnson Nutrition (NYSE:MJN) traded in a range yesterday that spanned from a low of $101.47 to a high of $104.05. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $102.33 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MJN: 99.23 (+0.84)

Mead Johnson sales up in U.S.
at Investor's Business Daily - Thu Oct 23, 5:59PM CDT
The children's nutrition products maker said Q3 earnings edged up to 92 cents per share from 91 cents in Q3 '13, beating estimates by 2 cents a share. Mead Johnson's (MJN) revenue grew 3.8% to $1.09 bil in Q3, topping consensus for $1.08 bil on...
MJN: 99.23 (+0.84)

Best U.S. Stock Ideas Today: 10/20/14
Aviate - Seeking Alpha - Thu Oct 23, 4:44PM CDT
Altera (NASDAQ: ALTR ): base station tailwinds and market position solid Fortinet (NASDAQ: FTNT ): execution and product cycle tailwinds continue NXP Semiconductor (NASDAQ: NXPI ): another beat and raise Mead Johnson (NYSE: MJN ): well...
MXIM: 29.74 (+0.15), ALTR: 35.26 (+0.04), CAB: 50.67 (+1.21), NXPI: 74.50 (+0.96), LL: 55.77 (-0.80), NOK: 8.12 (+0.11), TSCO: 73.35 (-1.21), DNKN: 47.34 (+0.30), MJN: 99.23 (+0.84), CRI: 77.65 (-1.51), DF: 16.33 (+1.91), FTNT: 27.20 (+0.10)

Mead Johnson Nutrition's (MJN) CEO Peter Jakobsen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 12:30PM CDT

MJN: 99.23 (+0.84)

Mead Johnson Tops Q3 Earnings & Revenues, Retains View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 11:59AM CDT
Mead Johnson (MJN) expects dairy input costs to moderate in the near future, which is believed to fuel positive growth in overall profit margins.
ZLTQ: 27.64 (+0.15), MJN: 99.23 (+0.84), GWPH: 73.89 (-0.08), QDEL: 27.93 (+0.06)

Mead Johnson Nutrition (MJN) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 23, 8:25AM CDT

MJN: 99.23 (+0.84)

Mead Johnson Q3 revenues up 4%, affirms guidance
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:20AM CDT

MJN: 99.23 (+0.84)

Mead Johnson beats Street 3Q forecasts
Automated Insights - Thu Oct 23, 7:01AM CDT
GLENVIEW, Ill. (AP) _ Mead Johnson Nutrition Co. (MJN) on Thursday reported third-quarter earnings of $187.6 million.
MJN: 99.23 (+0.84)

Mead Johnson Nutrition beats by $92.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 6:42AM CDT

MJN: 99.23 (+0.84)

Mead Johnson Reaffirms Full-Year EPS Guidance; Third Quarter Revenue Rises Four Percent and Increases Seven Percent on a Constant Dollar Basis
Business Wire - Thu Oct 23, 6:32AM CDT
Mead Johnson Nutrition Company (NYSE: MJN) today announced its financial results for the quarter and year-to-date period ended September 30, 2014.
MJN: 99.23 (+0.84)

Upcoming Earnings Releases, Quarterly Earnings, Spin-Off, and Market Activity - Research Reports on Mead Johnson, Philip Morris, GoPro, Kimberly-Clark and Kraft Foods
PR Newswire - Wed Oct 22, 8:00AM CDT
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), GoPro, Inc. (NASDAQ: GPRO), Kimberly-Clark Corporation (NYSE: KMB) and Kraft Foods Group, Inc. (NASDAQ: KRFT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7365-100free.
GPRO: 75.49 (-3.57), PM: 88.34 (+0.22), MJN: 99.23 (+0.84), KMB: 113.81 (+0.57), KRFT: 57.81 (-0.06)

Will Mead Johnson (MJN) Surprise Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 2:00PM CDT
Mead Johnson (MJN) sticks to its commitment of investing aggressively in research and development for innovation of products in the near as well as the long term.
MJN: 99.23 (+0.84), ABAX: 52.72 (+1.09), HTWR: 78.06 (+1.52), HSP: 56.02 (-0.30)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading